Spravato® (esketamine) rejected by NICE for treatment-resistant depression

Written by Sharon Salt, Senior Editor

4 September 2020 Spravato® (esketamine) receives second rejection by NICE for treatment-resistant depression On 3 September 2020, the National Institute for Health and Care Excellence (NICE) published a second draft guidance for Spravato® (esketamine) nasal spray in combination with a selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor, for adults living with treatment-resistant major depressive disorder who have not responded to at least two different antidepressants. The nasal spray has been rejected for a second time due to uncertainties surrounding its cost.  Esketamine was first rejected by NICE in January following concerns over its clinical and cost–effectiveness. However,...

To view this content, please register now for access

It's completely free